The Lilly Open Innovation Drug Discovery Program (OIDD)
Posted by
Daniel Robertson
on 2013-09-13
Through OIDD, Lilly has established a network of top global research talent at academic and biotech institutions to provide them access to proprietary, in vitro phenotypic and target-based assays (PD2 and TargetD2). This partnership is supported by the program’s website portal and application, which lowers the barrier for collaborations between investigators working inside and outside the Lilly walls. Although ChemAxon tools have been foundational to this project from the start, recently Lilly has been partnering with ChemAxon to deliver additional design and property tools for OIDD investigators to use as part of this initiative.
Related content
13 07 2022
< 1 minute
ICCS 2022 - Translating data to predictive models
Biological, chemical and physical properties of molecules are encoded in their molecular structure....
13 12 2021
< 1 minute
Cheminfo Stories Virtual UGM 2021 Asia Pacific Edition: Deep dive in the future of chemical patent drafting and in-house IP management
Writing chemical patents with Markush claims is a time-consuming, complex and business-critical...
13 12 2021
< 1 minute
Cheminfo Stories 2021 Virtual UGM Asia Pacific Edition: Design of new compounds from the available chemical space
In computational compound design workflows, the analysis of the available chemical space is an...
13 11 2021
< 1 minute
Cheminfo Stories 2021 Virtual UGM | Boost analytical experiments with phys-chem properties
TRY CHEMICALIZE Log in for videos & slides